12 recruiting, 11 completed, 8 unknown, 2 active not recruiting. 10 Phase 2, 7 Not applicable, 5 Phase 1, 2 Phase 3, 1 Early Phase 1.
Follow Pseudomyxoma Peritonei: new trials by email Literature Review of Pseudomyxoma Peritonei trials Research Report on Pseudomyxoma Peritonei
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE) Intestinal, Multivisceral or Modified Multivisceral Transplantation, Alemtuzumab, Tacrolimus - Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum | Phase 2 | Not yet recruiting | Case Comprehensive Cancer Center | 20 | 2026-11-01 | 2026-09-24 |
| Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms Metformin - Appendiceal Mucinous Neoplasm, Pseudomyxoma Peritonei | Phase 2 | Recruiting | University of California, Irvine | 15 | 2026-06-18 | 2026-07-13 |
| The Appendix Cancer PMP Research Foundation Natural History Study/Patient Registry Appendix Cancer, Pseudomyxoma Peritonei | Recruiting | Appendix Cancer Pseudomyxoma Peritonei Research Foundation | 10000 | 2026-02-02 | 2026-08-17 | |
| Proactive Temperature Management in CRS-HIPEC for Prevention of Delirium Proactive Goal-Directed Temperature Management, Standard Reactive Temperature Management - Pseudomyxoma Peritonei, Postoperative Delirium (POD) | Not applicable | Not yet recruiting | Aerospace Center Hospital | 174 | 2026-02-01 | 2026-01-30 |
| Ventral Hernias Following Cytoreductive Surgery : Incidence, Risk Factors and Surgical Management. Ventral Hernias, Cytoreductive Surgery | Recruiting | Jules Bordet Institute | 500 | 2026-01-20 | 2026-03-05 | |
| One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei One HIPEC session, Three HIPEC sessions - Pseudomyxoma Peritonei | Not applicable | Recruiting | Beijing Tsinghua Chang Gung Hospital | 132 | 2025-11-01 | 2026-01-09 |
| Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei Pseudovax, Molgramostim, Tislelizumab - Pseudomyxoma Peritonei | Early Phase 1 | Recruiting | Oslo University Hospital | 10 | 2025-10-13 | 2026-01-14 |
| Flura-seq for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei intravenously inject with 5-FU (400 mg/m2) - Pseudomyxoma Peritonei | Not applicable | Completed | Beijing Tsinghua Chang Gung Hospital | 36 | 2025-02-17 | 2026-01-06 |
| Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP) Mitomycin c - Pseudomyxoma Peritonei | Phase 3 | Recruiting | University of Southampton | 176 | 2024-12-04 | 2026-02-19 |
| Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients Capecitabine 1250 mg/m2 /day - Cyclophosphamide 50Mg/day - Pseudomyxoma Peritonei | Phase 2 | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 31 | 2024-11-22 | 2025-01-30 |
| Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery CSL511 Fibrinogen concentrate (human), Cryoprecipitate - Acquired Fibrinogen Deficiency | Phase 3 | Recruiting | CSL Behring | 90 | 2024-10-01 | 2026-10-13 |
| BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei Bromelain, Acetylcysteine, Interventional radiology insertion of drain - Pseudomyxoma Peritonei, Peritoneal Cancer | Phase 2 | Unknown | Mucpharm Pty Ltd | 62 | 2022-05-01 | 2022-03-15 |
| ERAS® Guidelines Validation of CRS With or Without HIPEC Pre-ERAS® phase (current clinical practice), Post-ERAS® implementation phase - Peritoneal Diseases | Unknown | Hospices Civils de Lyon | 288 | 2021-10-01 | 2022-01-11 | |
| Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis Cardiac coherence, Standard care - Peritoneal Carcinomatosis, Pseudomyxoma Peritonei | Not applicable | Recruiting | Institut du Cancer de Montpellier - Val d'Aurelle | 60 | 2021-09-21 | 2026-01-16 |
| Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei Bromelin, N-Acetylcysteine - Pseudomyxoma Peritonei | Phase 1 | Unknown | Maimónides Biomedical Research Institute of Córdoba | 10 | 2021-09-13 | 2022-06-02 |
| Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC Mitomycin C, flat dose 40 mg, Mitomycin C, weight-based dose 12.5 mg/m2 - Peritoneal Carcinomatosis | Phase 2 | Recruiting | Prakash Pandalai | 100 | 2021-06-04 | 2026-04-01 |
| Severe Neutropenia After HIPEC Using Mitomycin-C Intraoperative blood and peritoneal fluid samplings during HIPEC - Colorectal Cancer Metastatic, Cancer Metastatic to the Peritoneal Cavity | Completed | Gangnam Severance Hospital | 74 | 2021-05-20 | 2023-08-07 | |
| A Study of SGN-STNV in Advanced Solid Tumors SGN-STNV - Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms | Phase 1 | Terminated | Seagen Inc. | 111 | 2021-01-18 | 2025-02-07 |
| What Are the Experiences of Patients With Pseudomyxoma Peritonei? Pseudomyxoma Peritonei, Cytoreductive Surgery | Withdrawn | University of Southampton | 2019-11-01 | 2020-01-31 | ||
| Phase I Trial HIPEC With Nal-irinotecan nanoliposomal irinotecan - Peritoneal Cancer, Pseudomyxoma Peritonei | Phase 1 | Completed | Stony Brook University | 18 | 2019-10-22 | 2022-05-06 |
Showing 20 of 37. Sign in to see all of them.
Appendiceal Neoplasms (10) · Peritoneal Neoplasms (10) · Colorectal Neoplasms (8) · Adenocarcinoma, Mucinous (5) · Stomach Neoplasms (5) · Carcinoma, Ovarian Epithelial (3) · Endometrial Neoplasms (3) · Fallopian Tube Neoplasms (3) · Gallbladder Neoplasms (3) · Mesothelioma (3) · Ovarian Neoplasms (3) · Pancreatic Neoplasms (3) · Uterine Cervical Neoplasms (3) · Vulvar Neoplasms (3)
Carcinoma (37) · Neoplasms by Histologic Type (37) · Neoplasms, Glandular and Epithelial (37) · Adenocarcinoma (36) · Neoplasms (36) · Neoplasms, Cystic, Mucinous, and Serous (35) · Adenocarcinoma, Mucinous (32) · Digestive System Diseases (21) · Neoplasms by Site (21) · Digestive System Neoplasms (20) · Gastrointestinal Diseases (16) · Gastrointestinal Neoplasms (16) · Intestinal Diseases (15) · Intestinal Neoplasms (15) · Abdominal Neoplasms (10)
Hyperthermic Intraperitoneal Chemotherapy (3) · Mitomycin (3) · Acetylcysteine (2) · Bromelains (2) · Capecitabine (2) · Fluorouracil (2) · Leucovorin (2) · Oxaliplatin (2) · Surveys and Questionnaires (2) · Alemtuzumab (1) · Amoxicillin (1) · Behavior Therapy (1) · CTLA-4 Antigen (1) · Carboplatin (1) · Cisplatin (1)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (3) · Beijing Tsinghua Chang Gung Hospital (2) · Case Comprehensive Cancer Center (2) · Hospices Civils de Lyon (2) · Mercy Medical Center (2) · Oslo University Hospital (2) · University of Southampton (2) · Aerospace Center Hospital (1) · Albert Einstein College of Medicine (1) · Appendix Cancer Pseudomyxoma Peritonei Research Foundation (1) · CSL Behring (1) · Edward Hospital (1) · Gangnam Severance Hospital (1) · Institut du Cancer de Montpellier - Val d'Aurelle (1) · Jules Bordet Institute (1)
United States (16) · Italy (5) · France (4) · United Kingdom (4) · Belgium (3) · China (3) · Spain (3) · Canada (2) · Norway (2) · Switzerland (2) · Argentina (1) · Australia (1) · Austria (1) · Denmark (1) · Germany (1)
Armando Sardi, MD (2) · Alessandra Raimondi, MD (1) · Alvaro Arjona Sanchez, MD (1) · Armando Sardi, M.D. (1) · Barbara Andersen, PhD (1) · Deborah Shelton (1) · Dr. Erin P. Ward, MD (1) · Edward Levine, MD (1) · Estelle Guerdoux-Ninot, MD (1) · Faheez Mohamed, MBChB, MD, FRCS (1) · Gabriel Liberale, MD, Phd (1) · George I Salti, MD (1) · Georgios Georgakis, MD (1)
PMID 36410913, PMID 23844722, PMID 28212684, PMID 30473706, PMID 30862609, PMID 31262599, PMID 31969335, PMID 32826114, PMID 32873454, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34716198, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790
2019 (1), R21CA135005 (1), U10CA180888 (1)